Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233843 | 0.87 | TDP1 (0.58) | GLSRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6699936 | 0.85 | GLS (0.71) | GLSCASP3RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1553324 | 0.85 | TDP1 (0.61) | GLSRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL8332453 | 0.84 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL1553659 | 0.84 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL8324987 | 0.84 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL8328633 | 0.84 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL3843934 | 0.84 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL8326959 | 0.82 | TDP1 (0.49) | GLSRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6214684 | 0.82 | TDP1 (0.49) | GLSRAB9ASMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337467-B | Method for preparing colorant composition and colorant composition prepared thereby | 株式会社LG化学 | 2021-08-27 | — | — | CN | claimed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8524781-B2 | Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells | UNIVERSITY OF CAPE TOWN (ZA) | 2013-09-03 | — | — | US | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| CN-102256983-A | Spirooxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-11-23 | — | — | CN | claimed |
| CN-102171184-A | Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells | UNIV CAPE TOWN | 2011-08-31 | — | — | CN | claimed |
| US-20110190368-A1 | Organosulfur Compounds, a Method of Making Organosulfur Compounds and their Use for Inhibiting the Growth of Tumour Cells | UNIVERSITY OF CAPE TOWN (ZA) | 2011-08-04 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| EP-2321271-A1 | ORGANOSULFUR COMPOUNDS, A METHOD OF MAKING ORGANOSULFUR COMPOUNDS AND THEIR USE FOR INHIBITING THE GROWTH OF TUMOUR CELLS | University of Cape Town (ZA) | 2011-05-18 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| EP-0641356-B1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC (US) | 1998-04-22 | — | — | EP | claimed |
| US-5708001-A | TESTOSTERONE-5A-REDUCTASE INHIBITORS | GLAXO WELLCOME INC. (US) | 1998-01-13 | — | — | US | claimed |
| WO-1997013810-A1 | SULFO BENZ[e]INDOCYANINE FLUORESCENT DYES | SORIN BIOMEDICA CARDIO S.P.A. (IT) | 1997-04-17 | — | — | WO | claimed |
| WO-1997003783-A9 | METALLOPROTEINASE INHIBITORS | — | 1997-04-03 | — | — | WO | claimed |
| WO-1997003783-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| US-5543406-A | TREATING ANDROGEN RESPONSIVE OR MEDIATED DISEASE | GLAXO WELLCOME, INC. (US) | 1996-08-06 | — | — | US | claimed |
| EP-0674651-A1 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1995-10-04 | — | — | EP | claimed |
| EP-0641356-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1994014833-A2 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1993013124-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO INC. (US) | 1993-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190368-A1 | Organosulfur Compounds, a Method of Making Organosulfur Compounds and their Use for Inhibiting the Growth of Tumour Cells | OR10J3, RCOR3, CBR3 | GLS 741/4885CASP3 932/4885RAB9A 836/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | GLS 1437/4885CASP3 518/4885RAB9A 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.